EFFICACY OF MONTELUKAST ADDED TO INHALED BUDESONIDE IN COMPARISON OF INHALED BUDESONIDEON CONTROL OF MILD TO MODERATE ASTHMA IN CHILDREN
Narmin Hajo, Ghazal Dib, Amal Al-Hakim
Abstract
Narmin Hajo, Ghazal Dib, Amal Al-Hakim
Abstract
Background: While Guideline recommends daily treatment of corticosteroids to control asthma symptoms, Montelukast, a leukotriene receptor antagonist, is effective in treating asthma symptoms. Objective: To test the hypothesis that combined administration of multiple doses of inhaled Budesonide and oral montelukast provides additional benefit compared with Budesonide alone in children patients with mild and moderate severity of persistent asthma. Methods: An open Randomized trails study included 120 patients presenting to the clinic at Tishreen University Hospital over one year from March 2020 to March 2021. The patients were randomized to two equal groups: inhaled Budesonide only (group A) and inhaled Budesonide with oral montelukast (group B) by inhalation chamber over 12 weeks. All clinical variables by fill out a questionnaire, pulmonary functions (PEF, FEV1) were recorded at the baseline, 6, and 12 weeks. Results: The results showed that adding Montelukast to inhaled Budesonide improves the FEV1, PEF values, and quality of…
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Background: While Guideline recommends daily treatment of corticosteroids to control asthma symptoms, Montelukast, a leukotriene receptor antagonist, is effective in treating asthma symptoms. Objective: To test the hypothesis that combined administration of multiple doses of inhaled Budesonide and oral montelukast provides additional benefit compared with Budesonide alone in children patients with mild and moderate severity of persistent asthma. Methods: An open Randomized trails study included 120 patients presenting to the clinic at Tishreen University Hospital over one year from March 2020 to March 2021. The patients were randomized to two equal groups: inhaled Budesonide only (group A) and inhaled Budesonide with oral montelukast (group B) by inhalation chamber over 12 weeks. All clinical variables by fill out a questionnaire, pulmonary functions (PEF, FEV1) were recorded at the baseline, 6, and 12 weeks. Results: The results showed that adding Montelukast to inhaled Budesonide improves the FEV1, PEF values, and quality of…
Key concepts: Budesonide, Montelukast, Medicine, Asthma, Leukotriene receptor, Inhalation, Randomized controlled trial, Guideline